We're thrilled to be expanding our operation to Devens and look forward to becoming a part of this exciting community filled ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Bristol Myers Squibb will cut $2 billion in costs by the end of 2027, a move aimed at long-term growth as the company prepares for patent expirations on key treatments, CNBC reported Feb. 6.

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

BRISTOL-MYERS SQUIBB ($BMY) posted quarterly earnings results on Thursday, February 6th. The company reported earnings of $1.67 per share, beating estimates of $1.47 ...

Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth. The company also issued full ...

Shares in Bristol-Myers Squibb fell more than 4% in premarket trading Thursday, after the drug maker gave 2025 guidance that undershot analyst expectations. Bristol expects sales of about $45.5 ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

PRINCETON, N.J., January 31, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...